신경병증성 통증 치료제 파이프라인 분석 - 2026년(Q2 인사이트 및 임상시험)

Neuropathic pain results from injury or dysfunction of the somatosensory nervous system and remains one of the most challenging chronic pain conditions to treat. Current therapies, including gabapentinoids, serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, topical agents, and selected opioids, frequently provide incomplete symptom relief and are associated with tolerability limitations. Consequently, pharmaceutical developers are increasingly focusing on mechanism-specific therapies that selectively target the biological pathways responsible for chronic pain generation rather than providing generalized analgesia.

Market Drivers

Growing Burden of Neuropathic Disorders

• Increasing global prevalence of diabetes, cancer survivorship, chemotherapy-related neuropathy, spinal disorders, and neurodegenerative diseases continues expanding the addressable patient population and driving demand for innovative therapies.

Demand for Non-Opioid Therapeutics

• Growing concern regarding opioid dependence and long-term safety is accelerating pharmaceutical investment in highly selective non-opioid therapies capable of providing sustained pain relief while minimizing central nervous system adverse effects.

Advances in Molecular Neuroscience

• Improved understanding of ion channels, neuroimmune signaling, inflammatory mediators, and neuronal regeneration has enabled the identification of numerous validated therapeutic targets that support first-in-class drug development.

Precision Medicine

• Biomarker-guided patient selection, genetic profiling, and translational neuroscience are improving clinical trial design, increasing development efficiency, and supporting personalized treatment strategies.

Market Restraints

High Clinical Development Risk

• Neuropathic pain studies often experience significant placebo responses, heterogeneous patient populations, and variable clinical outcomes, increasing development uncertainty and costs.

Disease Complexity

• Multiple disease mechanisms contribute to neuropathic pain, making universal treatment approaches difficult and requiring highly targeted therapeutic strategies.

Stringent Regulatory Expectations

• Regulatory authorities increasingly require durable efficacy, long-term safety, clinically meaningful pain reduction, and robust patient-reported outcomes before approving innovative therapies.

Pipeline and Technology Insights

• The global neuropathic pain drug pipeline can be segmented by clinical development phase, mechanism of action, drug modality, target indication, molecule type, sponsor type, regulatory status, and geography.
• By clinical development phase, the pipeline includes preclinical, Phase I, Phase II, Phase III, and filed/under regulatory review programs. Most pipeline activity remains concentrated in early-stage development as companies validate novel biological targets before progressing into pivotal studies. Phase II programs represent one of the most active stages of clinical development.
• By mechanism of action, investigational therapies target selective sodium channel modulators, calcium channel modulators, TRP channel modulators, NMDA receptor modulators, cannabinoid-based therapies, neuroimmune modulators, neurotrophic approaches, inflammatory signaling pathways, and other emerging biological targets. Selective sodium channel inhibition remains one of the most active areas of innovation because of its potential to provide effective analgesia with reduced systemic adverse effects.
• By drug modality, the pipeline includes small molecules, biologics, monoclonal antibodies, RNA therapeutics, gene therapies, cell therapies, and regenerative medicine platforms. Small molecules continue to dominate development because of oral administration, established manufacturing capabilities, and well-defined regulatory pathways, while advanced biologics and genetic therapies represent emerging areas of innovation.
• By target indication, pipeline development addresses diabetic peripheral neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, trigeminal neuralgia, small fiber neuropathy, radiculopathy, central neuropathic pain, and other neuropathic pain disorders. Diabetic peripheral neuropathy remains the largest commercial opportunity because of its growing global prevalence.

Pipeline Trends

• The neuropathic pain drug pipeline continues evolving through scientific innovation.

Key trends include:

• Expansion of selective sodium channel inhibitor development.
• Increasing investment in non-opioid therapeutics.
• Growth of RNA therapeutics and gene therapy programs.
• Greater adoption of biomarker-guided clinical development.
• Increased application of artificial intelligence in drug discovery.
• Expansion of precision medicine strategies.
• Stronger licensing agreements and biotechnology partnerships.

Regional Insights

• North America remains the leading region for neuropathic pain drug development because of advanced neuroscience research infrastructure, strong biotechnology investment, supportive regulatory pathways, and extensive clinical trial activity. The United States hosts many of the world's leading pharmaceutical and biotechnology companies developing next-generation pain therapeutics.
• Europe continues to maintain strong pipeline activity through collaborative neuroscience research, standardized clinical development frameworks, and active academic-industry partnerships supporting innovation across multiple therapeutic modalities.
• Asia-Pacific is rapidly emerging as an important development region owing to increasing diabetes prevalence, expanding pharmaceutical research capabilities, improving healthcare infrastructure, and greater investment in translational neuroscience. China, Japan, South Korea, Australia, and India continue attracting multinational clinical development programs.
• Latin America and the Middle East & Africa continue strengthening participation in multinational development programs as healthcare infrastructure, regulatory systems, and neurological disease management continue improving.

Pipeline Landscape

• The current neuropathic pain pipeline demonstrates substantial scientific diversification compared with previous decades. Companies are moving beyond conventional analgesics toward therapies targeting validated molecular mechanisms such as sodium channels, neuroimmune pathways, kinase signaling, inflammatory mediators, and neuronal regeneration. Recent industry developments include Sangamo Therapeutics receiving FDA Fast Track designation for ST-503 for small fiber neuropathy, Toray Industries licensing TRK-750 to Sanodyne Therapeutics, and MIRA Pharmaceuticals initiating Phase I development of Ketamir-2 for neuropathic pain.

Future Outlook

• The future neuropathic pain drug pipeline will increasingly emphasize personalized medicine, biomarker-driven development, selective ion-channel pharmacology, regenerative medicine, RNA therapeutics, and artificial intelligence-assisted drug discovery. Continued advances in molecular neuroscience are expected to improve target validation, reduce clinical development risk, and accelerate commercialization of innovative non-opioid therapies through 2035.

Conclusion

• The Global Neuropathic Pain Drug Pipeline Analysis demonstrates a rapidly evolving innovation landscape supported by growing disease prevalence, expanding scientific understanding, and increasing demand for safer non-opioid pain therapies. Although placebo response, disease heterogeneity, and stringent regulatory expectations remain significant challenges, continued advances in mechanism-based drug development, precision medicine, and translational neuroscience are expected to create substantial opportunities for pharmaceutical companies, biotechnology firms, researchers, healthcare providers, and investors.

Key Benefits of this Report

• Comprehensive assessment of the global neuropathic pain drug pipeline.
• Detailed evaluation of investigational therapies across all stages of development.
• Analysis of mechanisms of action, therapeutic modalities, and innovation trends.
• Competitive intelligence covering pipeline assets, licensing activity, regulatory developments, and commercialization opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, researchers, healthcare providers, consultants, and investors.

What Businesses Use Our Reports For

• Pipeline benchmarking, portfolio prioritization, clinical development planning, licensing evaluation, partnership identification, competitive intelligence, investment analysis, commercialization strategy, regulatory planning, and long-term strategic decision-making.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global neuropathic pain drug pipeline by clinical development phase, mechanism of action, drug modality, target indication, molecule type, sponsor type, regulatory status, and geography
• Evaluation of pipeline assets, clinical development progress, regulatory milestones, commercialization opportunities, competitive positioning, and innovation trends
• Assessment of precision medicine strategies, biomarker-guided development, artificial intelligence integration, licensing activities, strategic collaborations, and future therapeutic opportunities
• Analysis of selective sodium channel modulators, calcium channel modulators, TRP channel modulators, NMDA receptor modulators, cannabinoid-based therapies, neuroimmune modulators, neurotrophic approaches, small molecules, biologics, RNA therapeutics, gene therapies, cell therapies, regenerative medicine platforms, and emerging neuropathic pain drug candidates through 2035.

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Research Methodology
• 1.2. Research Scope
  • 1.2.1. Analysis by Company
  • 1.2.2. Analysis by Development Phase
  • 1.2.3. Analysis by Intervention Type
  • 1.2.4. Analysis by Clinical Trial Status
  • 1.2.5. Analysis by Geography
• 1.3. Data Sources and Validation
• 1.4. Definitions and Assumptions

2. DISEASE OVERVIEW

• 2.1. Introduction
• 2.2. Disease Classification
• 2.3. Causes and Risk Factors
• 2.4. Symptoms and Clinical Manifestations
• 2.5. Diagnosis
• 2.6. Current Treatment Landscape
• 2.7. Epidemiology and Disease Burden
• 2.8. Unmet Clinical Needs

3. EXECUTIVE SUMMARY

• 3.1. Clinical-Stage Pipeline Overview
• 3.2. Pipeline Distribution by Development Phase
• 3.3. Leading Companies by Clinical Trial Activity
• 3.4. Leading Investigational Drugs and Interventions
• 3.5. Geographic Clinical Trial Landscape
• 3.6. Key Pipeline Trends and Findings

4. NEUROPATHIC PAIN PIPELINE DYNAMICS

• 4.1. Drivers
• 4.2. Restraints
• 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

• 5.1. PIPELINE ANALYSIS BY COMPANY
  • 5.1.1. Vertex Pharmaceuticals
  • 5.1.2. Grunenthal
  • 5.1.3. Eli Lilly and Company
  • 5.1.4. Astellas Pharma
  • 5.1.5. Algiax Pharmaceuticals
• 5.2. PIPELINE ANALYSIS BY DEVELOPMENT PHASE
  • 5.2.1. Early Phase I
  • 5.2.2. Phase I
  • 5.2.3. Phase I/II
  • 5.2.4. Phase II
  • 5.2.5. Phase II/III
  • 5.2.6. Phase III
• 5.3. PIPELINE ANALYSIS BY INTERVENTION TYPE
  • 5.3.1. Drug
  • 5.3.2. Biological
  • 5.3.3. Genetic
• 5.4. PIPELINE ANALYSIS BY CLINICAL TRIAL STATUS
  • 5.4.1. Not Yet Recruiting
  • 5.4.2. Recruiting
  • 5.4.3. Active, Not Recruiting
  • 5.4.4. Completed
  • 5.4.5. Terminated / Withdrawn / Suspended
• 5.5. PIPELINE ANALYSIS BY GEOGRAPHY
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia-Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa
• 5.6. CLINICAL TRIAL AND PATIENT ANALYSIS
  • 5.6.1. Clinical Trials by Patient Enrollment
  • 5.6.2. Clinical Trials by Study Design
  • 5.6.3. Patient Age Eligibility
  • 5.6.4. Patient Sex Eligibility
• 5.7. SPONSOR AND COLLABORATION ANALYSIS
  • 5.7.1. Leading Commercial Sponsors
  • 5.7.2. Leading Academic and Research Sponsors
  • 5.7.3. Leading Collaborating Organizations
  • 5.7.4. Sponsor-Collaborator Analysis
• 5.8. RECENT AND UPCOMING PIPELINE ACTIVITY
  • 5.8.1. Recently Initiated Clinical Trials
  • 5.8.2. Newly Recruiting Clinical Trials
  • 5.8.3. Recently Completed Clinical Trials
  • 5.8.4. Late-Stage Trials Approaching Primary Completion
  • 5.8.5. Trials with Recently Posted Results

6. COMPANY PROFILES

• 6.1. Vertex Pharmaceuticals
• 6.2. Grunenthal
• 6.3. Eli Lilly and Company
• 6.4. Astellas Pharma
• 6.5. Algiax Pharmaceuticals

7. LIST OF TABLES

8. LIST OF FIGURES